GX-I7 is in second-stage clinical trials to confirm o see if it is effective in the treatment of COVID-19. Genexine has said that GX-I7 showed good efficacy when used in combination with a variety of immunotherapeutic agents. Once proven to be effective, KG Bio will apply for emergency use authorization.
Genexine will receive $27 million in down payment as well as milestone payments, which are paid when each milestone is achieved in clinical trials and commercialization, and 10 percent of sales paid separately as royalties. The company will conduct a pre-clinical test to confirm the toxicity of GX-I7 by spraying it to the nasal cavity.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.